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nomics, Edmonton, Alberta, CanadaIntroduction: The incidence of acute kidney injury (AKI) in hospitalized patients is rising, and survivors are
at high risk for cardiovascular events and mortality. Effective strategies that improve long-term outcomes
of AKI are unknown.
Methods: A retrospective cohort study was performed between 2008 and 2011. All subjects were followed
until 31 March 2013, with a minimum follow-up of 2 years. Participants were adults 18 years of age or
older, who developed AKI during a hospitalization and had chronic kidney disease (CKD) following
discharge (n ¼ 19,707 mean age 69.9 years, mean postdischarge estimated glomerular ﬁltration rate
(eGFR) 43.0 ml/min/1.73 m2). Exposure to statins was examined prior to the index hospitalization as well as
within 2 years following hospital discharge. The primary outcome was mortality; secondary outcomes
included all-cause re-hospitalization and cardiovascular events.
Results: Within 2 years of discharge, only 38.3% of the participants were prescribed a statin. After
adjustment for comorbidities, statin use prior to admission, demographics, baseline kidney function, and a
number of other factors, statin use was associated with lower mortality (hazard ratio, 0.74; 95% conﬁdence
interval, 0.69, 0.79) in AKI survivors with CKD. Patients who received a statin also had a lower risk of all
cause rehospitalization (adjusted hazarad ratio, 0.90; 95% conﬁdence interval, 0.85, 0.94). Statin use was
not associated with a reduction in cardiovascular events.
Discussion: Among AKI survivors with CKD, statin use was associated with a lower risk of mortality and
rehospitalization rates. This ﬁnding suggests that there is an opportunity to improve postdischarge care in
AKI survivors.
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).A cute kidney injury (AKI) is a common complica-tion in hospitalized patients, and has been
consistently associated with an increased risk of death,
de novo or worsening chronic kidney disease (CKD), and
end-stage renal disease (ESRD).1–5 Patients discharged
after an episode of AKI have a 40% increased risk of
death in the 2 years following hospitalization,6 and a
50% to 60% increased risk of cardiovascular events,
compared to patients who do not develop AKI.7 There
are currently no effective therapies targeting estab-
lished AKI; however, identifying and treating patients
with CKD following an episode of AKI may improvespondence: Neesh Pannu, University of Alberta, 11-107 CSB,
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International Reports (2016) 1, 279–287health outcomes. Although recently published data
suggested that nephrologist follow-up was associated
with a 24% reduction in risk of death after hospitaliza-
tion with severe AKI requiring dialysis,8 little is known
about processes of care that modify outcomes after
episodes of AKI.
Statins are effective for reducing cardiovascular
morbidity and mortality in patients with CKD.8–18 We
sought to evaluate whether the use of statins was
associated with better outcomes among patients with
CKD after AKI.
METHODS
Study Population and Data Sources
We used the Alberta Kidney Disease Network
population-based database, which has been described
in detail elsewhere.19 The study cohort20 included all
adults 18 years or older residing in Alberta who were279
CLINICAL RESEARCH S Brar et al.: Statin Use and Survival After AKIadmitted to the hospital between 1 July 2008 and 31
March 2011 and had an episode of AKI during hospi-
talization. To be eligible for inclusion, patients had to
have at least 1 outpatient serum creatinine (Scr) mea-
surement within 180 days prior to hospitalization to
establish baseline kidney function, $ 1 measurement
during the hospitalization to establish AKI, and $ 1
SCr, urine dipstick (udip), urine albumin to serum
creatinine ratio (ACR), or urine protein to serum
creatinine ratio (PCR) measurement in the follow-up
period after hospital discharge to establish CKD. If
participants had more than 1 hospitalization during
this period, only the ﬁrst was considered (index hos-
pitalization). Participants who died or progressed to
ESRD (estimated GFR [eGFR] < 15 ml/min per 1.73 m2,
chronic dialysis, prior kidney transplantation) before
or during the index hospitalization were excluded. The
cohort was restricted to patients who had CKD after an
AKI episode. All subjects were followed up from the
discharge date of their index hospitalization until 31
March 2013, with a minimum follow-up of 2 years.
The study was reviewed and approved by the
institutional review boards at the Universities of
Alberta and Calgary.
Assessment of Baseline Kidney Function
The Chronic Kidney Disease Epidemiology Collabora-
tion (CKD-EPI) equation was used to determine the
estimated glomerular ﬁltration rate (eGFR).21 Baseline
kidney function was deﬁned as the mean outpatient Scr
in the 180 days prior to the index hospitalization.
Identiﬁcation of Acute Kidney Injury
AKI was identiﬁed by changes between baseline (pre-
hospital) and peak in-hospital Scr. AKI was deﬁned as an
increase in serum creatinine by 50% or greater within
7 days or by 26.5 mmol/L within 48 hours and/or
requirement for acute dialysis within 7 days of the index
hospitalization. AKI severity was determined using the
consensus criteria for AKI staging from the recently
published Kidney Disease Improving Global Outcomes
(KDIGO) AKI guidelines.22 Requirement for acute dialysis
for AKIwas determined using a validated approach, based
on diagnosis and procedural administrative codes.23
Assessment of CKD After AKI
The presence of CKD was assessed using Scr, urine
ACR, urine PCR, or udip measured 90 days or more
after the AKI episode to allow sufﬁcient time for
recovery of renal function (Supplementary Figure S1).
A 90-day time frame for recovery was chosen based on
the Kidney Disease Outcomes Quality Initiative guide-
lines,24 which deﬁne CKD as a persistent decline in
kidney function lasting >90 days. If subjects had more280than 1 outpatient SCr measurement, the measurement
closest to 90 days was considered. Postdischarge CKD
was deﬁned as eGFR < 60 ml/min/1.73 m2, ACR > 30
mg/g, PCR > 150 mg/g, or Udip > trace, consistent
with the KDIGO CKD guidelines.25
Assessment of Medication Use After Discharge
Prescription drug information was obtained from the
Pharmaceutical Information Network (PIN) database. We
classiﬁed statin exposure into the following groups: no
previous prescription, new prescription (deﬁned as at
least 1 prescription within 2 years after discharge from
the index hospitalization), stopping a previous prescrip-
tion, and continuing a prescription. Patients were clas-
siﬁed in the continuing prescription group if they had at
least 1 prescription in the 6 months prior to admission
and at least 1 prescription within 2 years postdischarge.
High-dose statin was deﬁned as the highest dosage for
each statin drug (Supplementary Table S1).
Assessment of Comorbid Conditions
Relevant demographic characteristics, preexisting
comorbid conditions (deﬁned using validated algo-
rithms),20,26 hospitalizations and outpatient physician
visits (general practitioner as well as specialist visits),
details of the index hospitalization including primary
admission diagnosis, and intensive care unit stay were
obtained using hospitalization data, claims ﬁles, and
ambulatory care classiﬁcation system ﬁles. We obtained
primary International Classiﬁcation of Diseases (10th
revision) codes and used these to classify primary
admission diagnoses using a previously published
approach.26 Resource intensity weight, similar to diag-
nostic related group weight, was used to categorize acuity
and severity of illness.27,28 Cholesterol level was deﬁned
as the mean outpatient total cholesterol in the 1 year prior
to the index hospitalization. The cholesterol levels were
classiﬁed into 5 risk categories according to the Fra-
mingham coronary heart disease risk score.29 Patients
who did not have a cholesterol measurement during this
time period were classiﬁed in an unknown group.
Outcomes
The primary outcome was mortality; secondary out-
comes included all-cause re-hospitalization and car-
diovascular events. All outcomes were assessed after
the discharge date of the index hospitalization. All-
cause re-hospitalization was deﬁned as any hospitali-
zation occurring after the index hospitalization. All
hospitalizations were identiﬁed using AH data. All-
cause mortality was identiﬁed using administrative
data sources. Cardiovascular events were deﬁned as
myocardial infarction, stroke, or revascularization
procedure, as deﬁned by validated algorithms.30–32Kidney International Reports (2016) 1, 279–287
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Continuous variables were described using the mean
and SD or the median with interquartile range as
appropriate. Categorical variables were described as
proportions of the cohort.
Multivariable Cox proportional hazard models with
time-varying covariates were used to estimate the
association between use of statin following index hos-
pitalization and all-cause mortality, re-hospitalization,
and cardiovascular events. The adjusted models
included terms for age, sex, income quintile, aboriginal
race, location of residency, health care use preceding the
index hospitalization, Canadian Institute for Health In-
formation resource intensity weight, intensive care unit
admission during the index hospitalization, primary
diagnostic code for hospitalization, procedures associ-
ated with AKI (cardiac catheterization, cardiac and
abdominal aortic surgery), comorbid conditions, base-
line kidney function (based on eGFR), cholesterol level,
statin, angiotensin-converting enzyme inhibitor (ACEi),
angiotensin receptor blocker (ARB), and b-blocker use
in the 6 months preceding admission and following
discharge (Supplementary Figure S2). Time of origin was
the discharge date for the index hospitalization. TheHospital-acquired acute kidney 
injury between July 1st, 2008
and March 31st, 2011
N = 35,086
Survived to discharge 
without ESRD
N = 26,724 (76.2%)
Survived to 90 days 
postdischarge
N = 24,238 (90.7%)
CKD aer AKI:
N = 19 707 (81.3%)
Prior CKD: n = 12,
,
148 (61.6%)
de novo CKD: n = 7559 (38.4%)
Figure 1. Selection of study population after episode of hospital-acquired
stage renal disease.
Kidney International Reports (2016) 1, 279–287proportional hazard assumption was evaluated and
satisﬁed by examining plots of the log-negative-log
within-group survivorship functions versus log-time.
First use of statin was used to update the exposure
status during the course of the follow-up (i.e., a person
on a statin would contribute person time to the “no
statin use” before the ﬁrst statin was prescribed and
contribute person time to the “statin use” group after the
ﬁrst statin was prescribed). Patients were censored if
they moved out of the province or reached the end of the
study date (31 March 2013) for all outcomes. For the
secondary outcomes, patients were censored if they died.
Analyses were repeated after further categorizing
statin users into the following groups: new prescrip-
tion postdischarge, continuing a previous prescription
within 2 years postdischarge, and stopping use of a
pre-hospital admission prescription. In the sensitivity
analysis, we excluded patients who required acute
dialysis to determine whether associations were similar
in patients with less severe AKI. We also performed a
sensitivity analysis excluding patients with proteinuria
at any time during the study period to assess whether
associations were similar in patients with non-
proteinuric CKD. We repeated analyses after excludingDied (n = 6402) during index
hospitalizaon and had 
ESRD (n =  1960) before and 
during index hospitalizaon
N = 8362 (23.8%)
No CKD post-AKI:
N =  4531 (18.7%)
Died within 90 days 
aer discharge
N = 2486 (9.3%)
acute kidney injury (AKI). CKD, chronic kidney disease; ESRD, end-
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ease, to examine ﬁndings in patients less likely to have
pre-existing established cardiovascular disease. We
compared the effect of statin use after stratifying theTable 1. Characteristics of statin users and nonstatin users
All subjects
Number of subjects (%) 19,707
Age, yr, mean (SD) 69.9 (14.9)
Sex, male (%) 52.5
Aboriginal (%) 3.8
Income quintile
Lowest (level ¼ 1) (%) 24.9
Highest (level ¼ 5) (%) 15.9
Urban location (%) 83.7
Healthcare access 3-year preceding hospital admission, mean (median, IQR)
Number of hospitalizations 1.7 (1, 0–2)
Number of GP visits 50.8 (36, 21–64)
Number of nephrologist visits 1.1 (0, 0–0)
Number of cardiology visits 3.1 (0, 0–2)
Number of internist visits 7.2 (3, 0–8)
Number of emergency visits 5.8 (3, 1–6)
CIHI resource intensity weight, mean (SD) 3.1 (6.3)
Intensive care unit during hospitalization (%) 18.9
Primary diagnostic code for hospitalization (%)
Cardiovascular 18.4
Respiratory 9.1
Gastrointestinal 10.3
Infectious disease 4.6
Cancer 7.6
Orthopedic 4.6
Hematologic 5.8
Genitourinary 11.1
Injury/poisoning 5.1
Other disease 23.5
Procedure or condition during index hospitalization (%)
Sepsis 4.8
Cardiac surgery 2.7
Cardiac catheterization 3.7
Abdominal aortic aneurysm repair 0.5
Pneumonia 10.7
Liver failure 0.7
Acute myocardial infraction 10.1
Noncardiac surgery 17.0
Comorbid disease (%)
Diabetes 42.6
Hypertension 80.9
Myocardial infarction 13.0
Chronic heart failure 33.4
Stroke or TIA 23.1
Cancer 9.0
Liver disease 2.4
Peripheral vascular disease 7.2
Kidney function
Baseline eGFR, ml/min/1.73 m2, mean (SD) 62.3 (25.8)
Prior CKD (%) 61.6
Prior CKD deﬁned by eGFR 33.3
Prio CKD deﬁned by proteinuria 11.6
Prior CKD deﬁned by eGFR and proteinuria 16.7
282cohort according to whether patients had pre-existing
CKD or de novo CKD (post-AKI) patients. We also
compared outcomes in patients on high-dose versus low-
dose statins.Statin users NonLstatin users P value
7539 (38.3) 12,168 (61.7)
70.7 (12) 69.3 (16.5) <0.01
57.6 49.4 <0.01
3.2 4.2 <0.01
0.59
24.6 25.1
15.6 16.0
84.3 83.2 0.04
1.7 (1, 0–2) 1.8 (1, 0–2) 0.02
48.2 (37, 22–61) 52.4 (36, 20–66) <0.01
1.2 (0, 0–0) 1 (0, 0–0) <0.01
4.6 (0, 0–5) 2.2 (0, 0–1) <0.01
7.7 (3, 1–9) 6.9 (2, 0–8) <0.01
5.5 (3, 1–6) 6 (3, 1–7) <0.01
2.7 (4.4) 3.4 (7.2) <0.01
24.8 15.3 <0.01
26.0 13.6 <0.01
8.9 9.3 0.245
8.4 11.4 <0.01
3.8 5.1 <0.01
5.4 9.0 <0.01
4.9 4.4 0.09
6.2 5.5 0.04
10.4 11.5 0.02
4.5 5.4 <0.01
21.4 24.7 <0.01
3.8 5.4 <0.01
4.7 1.5 <0.01
6.5 1.9 <0.01
0.8 0.3 <0.01
10.0 11.2 0.01
0.2 1.0 <0.01
16.3 6.3 <0.01
15.3 18.1 <0.01
55.7 34.5 <0.01
90.5 74.9 <0.01
19.8 8.8 <0.01
38.3 30.4 <0.01
25.9 21.4 <0.01
7.8 9.6 <0.01
1.0 3.2 <0.01
10.0 5.4 <0.01
58.8 (23.1) 64.4 (27.1) <0.01
66.2 58.8 <0.01
34.0 32.9 <0.01
11.8 11.5 0.02
20.3 14.5 <0.01
(Continued on next page)
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Table 1. (Continued)
All subjects Statin users NonLstatin users P value
AKI stage (%) <0.01
AKI stage 1 75.9 77.9 74.6 <0.01
AKI stage 2 14.8 13.5 15.6 <0.01
AKI stage 3 (no dialysis) 7.1 6.2 7.6 <0.01
Dialysis 2.3 2.4 2.2 0.37
Baseline total cholesterol, mmol/l <0.01
<4.1 29.7 40.6 23.0 <0.01
4.155.17 18.7 20.6 17.5 <0.01
5.186.21 10.2 10.1 10.3 0.67
6.227.24 3.3 3.6 3.1 0.05
$7.25 1.3 1.9 1.0 <0.01
Unknown 37 23 45 <0.01
AKI, acute kidney injury; CIHI, Canadian Institute for Health Information; CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; TIA, transient ischemic attack.
Table 3. Hazard ratios of statin use after hospital discharge
Outcome
Adjusted
hazard ratio
(95% CI)
Number of
events
Follow-up
time in
person-yr
Crude
hazard ratio
(95% CI)
Survival 0.74 (0.69–0.79) 6758 53700.94 0.75 (0.71–0.79)
All cause
re-hospitalization
0.90 (0.85–0.94) 15,256 25144.77 0.94 (0.9–0.97)
Cardiovascular
event
0.95 (0.87–1.04) 3493 48764.46 1.54 (1.43–1.65)
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Patient Characteristics
Between 1 July 2008 and 31 March 2011, there were
35,086 patients 18 years of age or older residing in
Alberta with hospital-acquired AKI (Figure 1). Of these
participants, 26,724 (76.2%) survived to 90 days after
their AKI episode. The study cohort included 19,707
patients with CKD after the AKI episode: 12,148
(61.6%) had prior CKD and 7,559 (38.4%) had de novo
CKD (Figure 1). The mean patient age was 69.9 years,
52.5% were men, and 83.7% lived in an urban location
(Table 1). The mean number of hospitalizations during
the 3 years preceding the index hospitalization was
1.7 (interquartile range [IQR] 02), and 18.4% of
the cohort had a cardiovascular diagnostic code as
the diagnosis most responsible for the index hospital-
ization. The majority of participants (80.9%) had hy-
pertension, and a large number of patients had diabetes
(42.6%), chronic heart failure (33.4%), and history of
stroke or TIA (23.1%).
Primary Outcomes
More than one-half (54.4%) of the cohort were never
prescribed a statin, 12.0% received a new prescription,
and 26.3% were continued on a statin within 2 years
after hospital discharge. Only 7.3% of previous statin
prescriptions were not restarted after hospital
discharge (Table 2).Table 2. Number of patients (%) who were using statin before and
after index hospitalization
Within 6 months
before admission
2 yr After
discharge
Statin 6620 (33.6%) 7539 (38.3%)
Never
prescribed
New
prescription
Stopping
previous prescription
Continuing
prescription
Statin 10,729 (54.4%) 2358 (12.0%) 1439 (7.3%) 5181 (26.3%)
Kidney International Reports (2016) 1, 279–287Over a total of 53,700 person-years of follow up, the
adjusted hazard ratio for mortality associated with
statin use after hospital discharge, compared with no
statin use, was 0.74 (95% conﬁdence interval [CI], 0.69,
0.79). Statin use after hospitalization was also associated
with a lower risk of all cause re-hospitalization (hazard
ratio [HR], 0.90; 95% CI, 0.85, 0.94) (Table 3).
Both a new statin prescription (HR, 0.73; 95% CI,
0.66, 0.80) and continuing a previous prescription (HR,
0.76; 95% CI, 0.71, 0.81) after hospital discharge was
associated with better survival compared to no statin
use. There was also lower all-cause re-hospitalization in
both patients who were given a new statin prescription
or continued on a previous statin prescription after
hospital discharge, compared to no statin use (Table 4).
Sensitivity Analysis
In the sensitivity analysis excluding patients with
cardiovascular disease (n ¼ 15,116), those who usedCI, conﬁdence interval.
Adjusted factors: Angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor
blocker (ARB), b-blocker, and statin use within 6 months before admission, ACEI/ARB
and b-blocker after discharge, age, sex, income quintile, urban location, health care use
3 years before hospital admission, Canadian Institute for Health Information resource
intensity weight, intensive care unit, primary diagnostic code for hospitalization, pro-
cedure or condition during index hospitalization, comorbid disease, baseline kidney
function (estimated glomerular ﬁltration rate), and total cholesterol risk categories.
Separate Cox proportional hazard models with medication use as time-varying cova-
riates were ﬁt for the outcome of all-cause mortality, all-cause re-hospitalization, and
cardiovascular events. All patients were followed up for at least 2 years starting at the
date of hospital discharge, with further censoring for death, outmigration from Alberta,
and the end of study (31 March 2013) in the model ﬁt of all-cause re-hospitalization and
cardiovascular events, and for outmigration from Alberta and end of study in the model
ﬁt for mortality.
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Table 4. Hazard ratios of statin use for never prescribed, new
prescription, stopping previous prescription, or continuing previous
prescription
Outcome Statin use Hazard ratio (95% CI)
Survival Never prescribed 1
New prescription 0.73 (0.66–0.80)
Stopping previous prescription 1.00 (0.91–1.09)
Continuing prescription 0.76 (0.71–0.81)
All cause re-hospitalization Never prescribed 1
New prescription 0.85 (0.79–0.91)
Stopping previous prescription 0.98 (0.93–1.03)
Continuing prescription 0.91 (0.87–0.95)
Cardiovascular event Never prescribed 1
New prescription 0.92 (0.81–1.05)
Stopping previous prescription 1.01 (0.90–1.13)
Continuing prescription 1.00 (0.92–1.10)
Prescription 6 mo Before admission 2 yr After discharge
Never prescribed No prescription No prescription
New prescription No prescription At least 1 prescription
Stopping previous prescription At least 1 prescription No prescription
Continuing prescription At least 1 prescription At least 1 prescription
CI, conﬁdence interval.
Adjusted factors: Angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor
blocker (ARB), b-blocker and statin use within 6 months before admission, ACEI/ARB
and b-blocker after discharge, age, sex, income quintile, urban location, health care use
3 years before hospital admission, Canadian Institute for Health Information resource
intensity weight, intensive care unit, primary diagnostic code for hospitalization, pro-
cedure or condition during index hospitalization, comorbid disease, baseline kidney
function (estimated glomerular ﬁltration rate), and total cholesterol risk categories.
Separate Cox proportional hazard models with medication use as time-varying cova-
riates were ﬁt for the outcomes of all-cause mortality, all-cause re-hospitalization, and
cardiovascular events. All patients were followed up for at least 2 years starting at the
date of hospital discharge, with further censoring for death, outmigration from Alberta,
and the end of study (31 March 2013) in the model ﬁt of all-cause re-hospitalization and
cardiovascular events, and for outmigration from Alberta and end of study in the model
ﬁt for mortality.
CLINICAL RESEARCH S Brar et al.: Statin Use and Survival After AKIa statin after hospital discharge had lower mortal-
ity (HR, 0.70; 95% CI, 0.64, 0.76), and all-cause
re-hospitalization (HR, 0.90; 95% CI, 0.85, 0.95)
(Table 5). Exclusion of patients with the most severe
AKI requiring dialysis (n ¼ 19,250) and proteinuria
before or after the index hospitalization (n ¼ 15,792)
did not change results for survival, re-hospitalization
rates, or cardiovascular events (Table 5).
Statin use was associated with lower mortality and
all cause re-hospitalization in both patients with pre-
existing CKD and de novo CKD. Statin use was notTable 5. Hazard ratios of statin use for patients not requiring
dialysis, with no proteinuria and no pre-existing cardiovascular
disease
Hazard ratio (95% CI)
Excluding
dialysis patients
Excluding patients
with proteinuria
Patients without
pre-existing CVDa
Number of subjects 19,250 15,792 15,116
Survival 0.74 (0.69–0.79) 0.74 (0.69–0.80) 0.70 (0.64–0.76)
All-cause rehospitalization 0.89 (0.85–0.94) 0.89 (0.84–0.93) 0.90 (0.85–0.95)
Cardiovascular events 0.96 (0.87–1.05) 0.95 (0.86–1.04) 0.92 (0.81–1.05)
CI, conﬁdence interval; CVD, cardiovascular disease.
aPre-existing CVD includes acute myocardial infarction, coronary artery bypass grafting,
cardiac catherization, congestive heart failure, cerebrovascular accident (including all
stroke-related events), and percutaneous coronary interventions in the 3 years before
admission and during the index hospitalization.
284associated with lower risk of cardiovascular events in
patients with pre-existing or de novo CKD (Table 6).
Low-dose and high-dose statin had similar effects on
mortality, all-cause re-hospitalization, and cardiovas-
cular events (Table 7).
DISCUSSION
Using a large population-based cohort we characterized
statin use in patients with CKD after an episode of AKI
in the hospital. Over a follow-up period of at least 2
years after discharge, AKI survivors who were
dispensed a statin after the index hospitalization had a
lower risk of death compared to those with no statin
use. Statin use was also associated with a decreased risk
of all-cause re-hospitalization.
The risks of developing CKD following an episode of
AKI are well documented in both pediatric33 and adult34
cohort studies. Recent work from our group conﬁrms
that failure to recover renal function to within 25%
of baseline SCr within 90 days after moderate to severe
AKI is associated with an increased risk of long-term
mortality (adjusted HR, 1.26; 95% CI, 1.10, 1.43).35
Management of CKD after AKI may mitigate the risks
of progressive CKD and increased mortality. A recently
published systematic review of randomized controlled
trials conﬁrmed the importance of ACEi, ARB, b-blocker,
and statin use as effective therapies for the treatment of
CKD stages 1 to 3.36 Statins showed reduced mortality
and cardiovascular events versus placebo or control in
patients with impaired eGFR. To date no studies have
examined the effect of statin use in AKI survivors.
Conservative population based estimates of AKI
incidence in hospitalized adults are in the range of 3,000
per 100,000 person years,37 and the majority of these
patients will survive hospital discharge. Recent KDIGO
guidelines recommended that patients be followed up 3
months after an AKI episode to assess for CKD; however,
there has been a lack of information to guide the care that
these patients should receive. Based on our results, AKI
survivors may beneﬁt from statin therapy post-
discharge, an intervention that does not require
specialized care and could be readily implemented. In
our study, only 39.1% of the cohort who had CKD after
AKIwere dispensed a statin within 2 years of their index
hospitalization, despite their high risk proﬁle forTable 6. Hazard ratios of statin use after hospital discharge for
patients with prior chronic kidney disease (CKD) and de novo CKD
Outcome
Hazard ratio (95% CI)
Prior CKD De novo CKD
Number of subjects 12,148 7559
Survival 0.76 (0.70–0.83) 0.67 (0.59–0.77)
All cause rehospitalization 0.90 (0.85–0.96) 0.86 (0.79–0.94)
Cardiovascular events 0.96 (0.87–1.07) 0.92 (0.77–1.10)
Kidney International Reports (2016) 1, 279–287
Table 7. Hazard ratios of high- and low-dose statin use
Outcome Hazard ratio (95% CI) Number of subjects
Survival
Low-dose 0.74 (0.69–0.79) 6651
High-dose 0.71 (0.62–0.82) 888
No statin 1.00 [reference] 12,168
High-dose versus low-dose 0.97 (0.84–1.11) –
All-cause rehospitalization
Low-dose 0.89 (0.85–0.94) 4993
High-dose 0.91 (0.82–1.00) 679
No statin 1.00 [reference] 14,035
High-dose versus low-dose 1.01 (0.92–1.12) –
Cardiovascular events
Low-dose 0.94 (0.85–1.03) 6310
High-dose 1.10 (0.94–1.29) 815
No statin 1.00 [reference] 12,582
High-dose versus low-dose 1.18 (1.02–1.37) –
CI, conﬁdence interval.
A total of 888 patients used high-dose statin before death occurred or the end of the
follow-up period; 679 patients used high-dose statin before re-hospitalization after
discharge from the index hospitalization or the end of the follow-up period; and 815
patients used high-dose statin before a cardiovascular event occurred or the end of the
follow-up period.
S Brar et al.: Statin Use and Survival After AKI CLINICAL RESEARCHcardiovascular disease, and despite recently released
international guidelines for lipid management in CKD,
which recommends that adults >50 years of age with
eGFR < 60 ml/min/1.73 m2 should be treated with a
statin.38 Furthermore, 5.8% of statin prescriptions were
not restarted postdischarge. We also observed better
survival in the subgroup of patients who were given a
new statin prescription compared to those who did not
receive a statin. These ﬁndings suggest that there is an
opportunity to improve postdischarge care in AKI sur-
vivors with CKD.
Several recent studies have suggested that AKI is a
risk factor for cardiovascular disease and future car-
diovascular events.39 Our results showed a trend
toward a reduction in cardiovascular events in patients
who received a statin, although it was not signiﬁcant.
This may be explained by the fact that patients who
develop AKI and progress to CKD likely have unde-
tected or early cardiovascular disease.
Despite reporting outcomes adjusted for many
important confounders, there are some limitations to
our analysis, related primarily to the retrospective use
of administrative and laboratory data and observational
design. First, entry into the cohort was limited to
subjects who had $1 outpatient SCr measurement
within 180 days prior to hospitalization and >1 inpa-
tient SCr measurement performed as part of hospital
care in Alberta. However, repeated measurements of
SCr are common in patients hospitalized for acute
medical and surgical problems, and based on prior
work, patients who do not have SCr drawn after hos-
pitalization have outcomes similar to those who do not
have AKI; therefore, it is likely that we were able toKidney International Reports (2016) 1, 279–287capture all AKI patients at high risk for poor outcomes
after discharge. Second, we were unable to obtain
measures of some potentially important covariates such
as blood pressure, urine output, nutritional status, and
deconditioning after hospitalization with AKI. Third,
as patients were not randomized to different processes
of care, there is potential for treatment-by-indication
bias, whereby certain patient characteristics prompt
differences in prescription of a statin, thereby intro-
ducing confounding. However, because we expect that
patients at higher cardiovascular risk are more likely to
receive a statin, we expect that the direction of bias in
our study is toward the null, and thus the strength of
any observed associations between medications and
outcomes is likely conservative. It is also possible that
statin use was a marker of better follow-up care.
Finally, our exposure was deﬁned as a dispensed pre-
scription, and the rate of compliance among patients in
the statin group is likely not 100%.
CONCLUSIONS
The use of a statin in AKI survivors who progress to
CKD after hospital discharge is associated with lower
mortality and re-hospitalization. This observation re-
quires further evaluation in prospective studies eval-
uating postdischarge care strategies for AKI survivors.
In particular, our results suggest a need for a trial to
evaluate treatment with statin in survivors of AKI, to
determine whether this intervention improves long-
term outcomes in high-risk patients.
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